Premium
Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors: A case report and review of published cases
Author(s) -
Takahashi Toshiya,
Yamasaki Kenshi,
Terui Hitoshi,
Omori Ryoko,
Tsuchiyama Kenichiro,
Fujimura Taku,
Aiba Setsuya
Publication year - 2019
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.14998
Subject(s) - medicine , adalimumab , dermatology , hidradenitis suppurativa , scalp , follicular phase , etiology , follicular cyst , pathogenesis , pathology , necrosis , etanercept , tumor necrosis factor alpha , cyst , immunology , disease
Perifolliculitis capitis abscedens et suffodiens ( PCAS ) or dissecting cellulitis is a rare condition presenting deep follicular occlusions, follicular ruptures and follicular infections in the scalp area with unknown etiology, which consequently cause primary neutrophilic cicatricial alopecia by the repeated follicular inflammation. PCAS is categorized as one of the “follicular occlusion tetrad” along with hidradenitis suppurativa, acne conglobata and pilonidal cyst. In the pathogenesis of the follicular occlusion tetrad, the involvement of neutrophils and its activator tumor necrosis factor ( TNF ) have been discussed. Here, we report a case of PCAS that was successfully treated with adalimumab, a human anti‐ TNF monoclonal antibody. This is the first Asian case of PCAS that was improved by a TNF inhibitor.